Objective To compare the effectiveness and safety of budesonide-glycopyrrolate-formoterol, a twice daily metered dose inhaler, and fluticasone-umeclidinium-vilanterol, a once daily dry powder inhaler, ...

1 Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA 02120, USA 2 Division of Pulmonary and Critical Care Medicine, Department of ...

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first moderate or severe COPD exacerbation (HR 1.09, 95% CI 1.04-1.14) compared ...

MACE incidence in patients with COPD initiating triple therapy was 11.3/100/year vs 8.7/100/year in patients using LABA-ICS. In patients with chronic obstructive pulmonary disease (COPD), the first ...

Study Aim To describe treatment pathways 5 years prior to initiation of dual bronchodilator therapy (LABA+LAMA) or on triple inhaled therapy (ICS+LABA+LAMA), in single or separate inhalers, in ...

GlaxoSmithKline is set to launch its COPD triple therapy in the US - and must now ... of whom currently use three drugs in separate inhalers. The combination of an inhaled corticosteroid, long ...

GlaxoSmithKline’s (GSK) triple therapy for chronic obstructive pulmonary disease (COPD) has been approved ... patients use three drugs in separate inhalers and the combination of corticosteroid ...